CytoDyn (CYDY) Total Liabilities (2011 - 2026)

CytoDyn's Total Liabilities history runs 16 years deep, the most recent figure standing at $122.8 million for Q1 2026.

• Quarterly Total Liabilities rose 7.54% year-over-year to $122.8 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $122.8 million (up 7.54% YoY) and the FY2025 annual result came in at $114.1 million, down 10.79% from the prior year.
• Total Liabilities was $122.8 million for Q1 2026 at CytoDyn, down from $128.7 million in the prior quarter.
• Across five years, Total Liabilities topped out at $129.7 million in Q1 2024 and bottomed at $113.0 million in Q3 2025.
• A 5-year average of $121.1 million and a median of $122.7 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities retreated 19.28% — and 2025, when it grew 12.62%.
• CytoDyn's Total Liabilities stood at $123.0 million in 2022, then climbed by 0.47% to $123.6 million in 2023, then retreated by 7.57% to $114.3 million in 2024, then advanced by 12.62% to $128.7 million in 2025, then declined by 4.58% to $122.8 million in 2026.
• Business Quant data shows CYDY's Total Liabilities at $122.8 million in Q1 2026, $128.7 million in Q4 2025, and $113.0 million in Q3 2025.